Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi, after the French vaccine specialist announced it would not renew existing CEO Paul Hudson’s contract.

Citius Oncology has signed an exclusive distribution agreement with Uniphar to enable access to Lymphir in selected western ...

THX Pharma and Biocodex have entered into a strategic licensing agreement to further the development of two drug candidates, ...

The FDA’s refusal to review Moderna's flu vaccine, mRNA-1010, comes within a wider push from the US government to alter ...

Despite the FDA’s CNPV scheme generating high interest, the process around how voucher awards are prioritised remains unclear ...

Madrigal is eying an expansion of MASH blockbuster Rezdiffra’s capabilities via combination with precision siRNA gene ...

The upcoming patent cliff, the impact of geopolitical and policy issues, and a changing deal environment were discussed at ...

Every two years, South Korea adjusts the national health insurance (NHI) prices for existing listed products based on the ...

Novo and Hims & Hers have continually locked horns over the legality of obesity drug offerings. Hims & Hers has abandoned ...

Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector.

Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.

After more than a year out in the cold, the programme’s reauthorisation is a boost for rare disease therapy developers.